Take Feds’ Medicaid Funds

When the recent Supreme Court ruling upheld the constitutionality of the health care reform law, it also opened up new questions about Medicaid that were explored at length by Winthrop Quigleys UpFront piece Medicaid Expansion the Next N.M. Debate.

Although Gov. Susana Martinez has publicly questioned whether its in New Mexicos best interest to comply with expanding Medicaid starting in 2014 as part of the Affordable Care Act, opting out wouldnt just be a burden to my hospital and the patients I treat it would be turning down the deal of the decade.

The law expands health care coverage in two ways.

The first is by creating health insurance exchanges for individuals and small businesses to shop for comprehensive insurance plans at a subsidized rate. To her credit, the governor has moved New Mexico forward, and our state exchange is finally in the works.

The second is by extending eligibility for Medicaid. Medicaid, which currently only covers low-income citizens who meet certain conditions, will be expanded to cover all single adults making a little less than $15,000 per year and a family of four making about $30,000 a year. Expanding Medicaid alone would give coverage to an additional 170,000 New Mexico children and adults. But the Supreme Courts ruling gives states the option of rejecting this expansion and the federal dollars that come with it, as Quigley pointed out.

Rejecting this funding would be a disaster for New Mexico.

I saw the patients who would benefit from this expansion while I was training as a resident physician at University of New Mexico Health Sciences Center in Albuquerque. Most of them come from hardworking families. They play by the rules, pay their taxes and want whats best for their children.

But the astronomical cost of health insurance places it out of reach for their family budgets. As a result, too many of them cut back on the care I prescribe for their conditions and far too many of them skimp on preventative care that keeps them healthy in the first place all because they cant afford it. But even if I were unmoved by the precariousness of my patients financial stability, I would find the effect of the Medicaid expansion on my state and my countys fiscal well-being to be equally compelling.

Right now, hospitals and providers are treating the 24.7 percent of New Mexicans who are uninsured, and too often that treatment remains uncompensated care because the patient is simply unable to pay. In fiscal 2011, UNM alone reported providing $198 million in charity care and care for the uninsured.

Who pays for this uncompensated care? We all do.

Link:

Take Feds’ Medicaid Funds

Employers work on health mandate

Now that the Supreme Court has upheld most of President Obamas health care law, U.S. businesses by and large appear skeptical about Republican attempts to repeal the law and are rushing to comply with it, surveys show.

While the political drama over the law is far from over, businesses face significant penalties if they fail to comply with its mandates, including providing health care coverage to all full-time employees starting in 2014.

A survey by Mercer, a human resources consulting agency, immediately after the Supreme Courts June 28 ruling found that the majority of businesses had been waiting until the court acted before complying with the law.

After the high courts affirmation, the majority of businesses surveyed said they would start setting up systems for carrying out the mandate and other health reforms, with only 16 percent saying they will wait until after the November elections to see whether Republicans make any headway with their drive to repeal the law, Mercer said.

Mercer and other health care groups are advising businesses not to wait.

"Although the law still faces a contentious political outlook, employers should stay on track in their efforts to comply with the law as enacted or else they may face penalties," said David Rahill, head of Mercers health benefits division.

Many economists hoped the high courts decision would remove one of the major uncertainties that they believe have caused businesses to hesitate about hiring people this year. Providing health insurance to a typical employee costs an average of more than $10,000 a year, so it is a significant expense, especially for companies that employ mostly low-wage workers.

"The ruling eliminates one source of uncertainty," said Nigel Gault, an economist at IHS Global Insight. But, he said, Republican attempts to repeal the law and obstruct its implementation are inserting a new element of uncertainty into business planning.

The House passed a repeal bill by a mostly party-line vote last week, but the bill is not expected to advance in the Senate this year. For Congress to enact a repeal bill next year, Republicans would not only have to maintain control of the House, they would have to gain control of the Senate and the White House -- a scenario that is not given high odds by most political analysts.

Mercer said businesses will have to act quickly to implement new requirements that go into effect this year and next to provide benefit summaries to their employees, limit the size of flexible health-care accounts and increase withholding of Medicare taxes from high-income earners.

See original here:

Employers work on health mandate

Assemblyman Bill Monning: Affordable Care Act monumental step forward in health promotion

Assemblyman Bill Monning

What does the historic U.S. Supreme Court decision upholding federal health care reform, the Affordable Care Act, portend for California and Californians?

Since being signed into law by President Barack Obama in 2010, portions of federal health care reform have been enacted and more than 350,000 young adult Californians under the age of 26 have qualified for health care coverage under a parent's existing plan. Almost 11,000 individuals who were denied coverage by established plans because of a pre-existing medical condition have been enrolled in the Preexisting Condition Insurance Program. And, since 2010, young people under the age of 18 cannot be denied coverage due to a pre-existing condition; more than 350,000 Medicare enrollees have received up to $600 a year in assistance to buy prescription drugs [the doughnut hole]; more than 30,000 small business owners have used tax credits to help offset the costs of employer-sponsored health care coverage; and there are no lifetime caps or maximum limits on what health insurance will cover during the entire time you are enrolled in the plan. All of these benefits are already in effect in California.

It is interesting to note that when polled, many opponents of federal health care reform overwhelmingly approve of the rights and protections embodied in the law. Strident opponents do not believe the government should offer any support to individuals seeking health care services. Yet,

With the Supreme Court's decision, the ACA will extend health care access and eligibility to millions of Californians. The court held that Congress can mandate the implementation of a more comprehensive and cost effective health care delivery system.

While there is more work to do for California to fully implement the ACA by 2014, the California Legislature has been a pioneer in laying the groundwork and has already established the Health Benefit Exchange. The exchange will make it easier for people to buy health insurance products in an open and transparent marketplace.

In addition, I am working with my colleagues to develop policies that will assist consumers and advance health promotion and wellness in our state. I believe one of the strongest features of federal health care reform is its commitment to community-based medicine, including the promotion of health and wellness through the funding of prevention, wellness, immunization, and community-based health promotion. While there is no quick fix to control preventable diseases and illnesses, the ACA offers some of the critical tools and resources necessary to expand access to health care services and to direct more resources to disease prevention and health promotion.

There are those who will argue that federal health care reform falls short of a comprehensive and universal national health plan. Yet, amid the current polarized political dynamic in our nation, the Obama administration's achievement, affirmed by the U.S. Supreme Court, represents a monumental step forward in the promotion of health and health care access for all. For those families who have already received treatment for a loved one who would have otherwise been denied health treatment coverage, the ACA has indeed been transformative and for some, life-saving.

Assemblyman Bill Monning is chair of the Assembly Health Committee and represents the 27th Assembly District, which includes portions of Monterey, Santa Clara and Santa Cruz counties. Prior to his election to the Assembly, he was a professor at the Monterey College of Law and a professor of International Negotiation and Conflict Resolution at the Monterey Institute of International Studies.

Read more:

Assemblyman Bill Monning: Affordable Care Act monumental step forward in health promotion

Jansky Very Large Array Achieves First Light

July 22, 2012

Image Caption: The Jansky Very Large Array radio astronomy telescope array consists of twenty-seven, 230-ton, 25-meter diameter dish antennas that together comprise a single radio telescope system. Credit: National Radio Astronomy Observatory

redOrbit Staff & Wire Reports Your Universe Online

Researchers with the U.S. Naval Research Laboratory (NRL) and the National Radio Astronomy Observatory (NRAO) in New Mexico announced Friday that they had successfully achieved first light at low frequencies using the Jansky Very Large Array (JVLA) radio astronomy telescope.

Using five of the JVLAs 27 230-ton, 25-meter diameter very high-frequency (VHF) dish antennas, NRAO astronomer Dr. Frazer Owen was able to map the radio sky at 337 MHz on May 1, the NRL announced in a July 20 statement. The first light image comes as a new, wide-band receiver system developed by scientists and engineers from both organizations was being deployed on board the JVLA to extend its frequency range.

This initial demonstration of the telescopes interferometric imaging capabilities was called a key milestone by NRL officials, who added that it was strong verification that the new receivers have the sensitivity, stability, and coherence critical to the needs of the international radio and space science communities, with key benefits for both astronomical and ionospheric science applications.

The use of over 100 megahertz of bandwidth in the first image is a dramatic illustration of the breakthrough to instantaneous wideband systems at frequencies below one gigahertz, said Dr. Namir Kassim, section head of the NRL Radio Astrophysics Section. This represents a poorly explored part of the electromagnetic spectrum that is important for ionospheric and astrophysical research and to the Navys mission for navigation and communications.

The telescope is not currently at full strength, according to the Navy. A 2011 upgrade to the receivers made it so the JVLA was unable to operate at VHF capabilities between 30 MHz and 300 MHz, and only five of the observatorys telescopes have been outfitted with the new receivers. All 27 should be fully equipped by next summer, however, and the first light image has been called a critical step in that direction.

The loss of low-frequency capability to the worlds most powerful radio telescope was a set-back not only to the radio research community, but to continued astrophysics and ionospheric work critical to the needs of Navy communications and navigation, NRL radio astronomer Dr. Tracy Clarke said.

With the new greatly improved receivers and the demonstration that they work well with the JVLA, scientists are once again able to explore with greater veracity the low-frequency radio bands for high sensitivity astrophysics and high accuracy ionospheric research, Clarke added.

See the original post:

Jansky Very Large Array Achieves First Light

Digital Pathology FAQs

Courtesy of the Digital Pathology Association.

Answers to many key questions you may have been afraid of asking.

1. Q: Is digital pathology FDA approved for primary diagnosis?  

A: No, digital pathology is not FDA approved for primary diagnosis.  However, several manufacturers have received 510(k) clearances or specific uses.  Please refer to theregulatory page for more information.  

2. Q: What CPT codes can apply to digital pathology?

 A: (Reference chart below) 

CPT CODE(S)DESCRIPTIONDIGITAL PATHOLOGY APPLICATION
88300-88309Accession, examination, and reporting of gross and microscopicPrimary Diagnosis preformed on whole slide images*
88321Consultation and report on referred slides prepared elsewhereSecond opinion consultations preformed on whole slide images
88323Consultation and report on referred material requiring preparation of slidesSecond opinion consultations on whole slide images
88329, 88331, 88332Pathology consultation during surgery, frozen sectionFrozen section consultation preformed via live telepathology or on whole slide images
88360, 88361Morphometric analysis, tumor immunohistochemistry (eg. Her-2/neu, ER/PR), quantitative or semiquantitative, each antibody, manual or using computer assisted technologyManual or computer- assisted analysis of HER2, ER/PR, Ki-67, p53, etc**
88365, 88367, 88368In situ hybridization (eg. FISH), morphometric analysis (quantitative or semi-quantitative), manual or using computer assisted technology for each probeManual or computer assisted analysis of FISH*

*No manufacturers at this time are FDA approved for primary diagnosis. Refer to the Regulatory page for more information.  
** Some manufacturers have obtained 510(k) clearances for manual and/or quantitative analysis of Immunohistochemistry and/or FISH.  Please refer to the 510(k) clearance list [link to page] and the Regulatory page for more information.

3. Q: Do I need to validate my digital pathology system for clinical use? 
A: It is recommended by the College of American Pathologists (CAP), a CLIA accredited organization, that all institutions or practices considering the implementation of digital pathology for clinical diagnostic purposes must carry out their own validation.  For more information please refer to the Regulatory page.

 4. Q: Do I need to preform a validation if I am only doing the professional component (PC) of the diagnosis? 

A: It is recommended by the College of American Pathologists (CAP), a CLIA accredited organization, that all institutions or practices considering the implementation of digital pathology for clinical diagnostic purposes must carry out their own validation. However, it is up to the institution or practice who has implemented the digital pathology system to determine the scope of the validation study; specifically what will and will not be included as an intended use. Refer to the institution preforming the technical component (TC) for information on their validation of the digital pathology system and weather it is validated for the professional component (PC) of a primary or secondary diagnosis.

5. Q: How can digital pathology benefit patients? 
A: Often pathologists do not meet the patients they serve.  However, digital pathology provides the tools and innovation necessary to bridge the gap between a patient, their diagnosis, and their pathologist.  Digital pathology can illustrate and document key findings within a patient diagnosis to promote better communication between pathologists, other physicians, and patients.  Examples include a digital image imbedded into the pathology report, the delivery of a prognostic score based on computer assisted quantitative analysis, whole slide images of a patient case being discussed at a tumor board, or simply improving the turnaround time of a patient diagnosis.

6. Q: Is viewing a whole slide image on a computer monitor the same as viewing a glass slide under a microscope?  
A: Many pathologists believe the viewing experience of a whole slide image is better then a microscope.  When you look through the eye pieces of a microscope you have a limited field of view and can only view one slide. With digital pathology you can see more slides and more of the tissue all at once. In addition you can move the slide around, change objectives, and even focus up and down through the tissue - just like a microscope!

7. Q: What is the file size of a whole slide image and how should they be managed? 
A: Most scanners support capture resolutions of 0.5 microns/pixel (effective viewing magnification: 20X) or 0.275 microns per pixel (effective viewing magnification: 40X). The image file associated with a 20X scan of a 15mmx20mm tissue specimen is as large as 3.6GB and a 40X scanned image can be as large as 14.5GB. The images are compressed to more manageable sizes (25:1 compression or greater) such that there is an optimization between image quality, image file size, network bandwidth usage, and server and client resource utilization. For example, the 20X scan could be stored in a JPEG2000-compression file of size 144MB. The 40X image described above could be stored in a JPEG2000-compressed file of size 576MB. Digital Pathology images are about 10X that of Radiology images and will require more storage management through their useful life cycle.  For more information on how they should be managed please refer to the DPA white paper “Archival and Retrieval in Digital Pathology Systems.” 

8. Q: Is cloud (SaaS) storage secure and fast for digital pathology? 
A: Yes, cloud technology or Storage as a Service (SaaS) is growing in popularity and offers some significant benefits for primary storage and for replication of data.  Cloud based storage can lower storage costs, maintain or improve security and data integrity including HIPPA compliance, improve flexibility, and expand capacity when capacity resources are strained.  More information on cloud replication of data is provided in the DPA white paper “Archival and Retrieval in Digital Pathology Systems.”

9. Q: Are whole slide images DICOM compatible? 
A: Yes, however digital pathology solution manufacturers must support DICOM Supplement 145: Whole Slide Microscopic Image IOD and SOP Classes, finalized by the DICOM Standards Committee, and Working Group 26 for Pathology in 2010.

10. Q: Is digital pathology HIPAA compliant? 
A: The metadata associated with a whole slide image, but not the whole slide image itself, can contain protected health information (PHI) which is at the center of HIPAA compliancy.  However, most digital pathology manufacturers can support a HIPAA compliant solution by encrypting PHI sensitive metadata such as slide labels, hospital / patient / case / specimen information, etc.  Furthermore, procedures must be in place to protect PHI within the digital pathology system to reduce the risk of unauthorized access to the computer system.

11. Q: How long does it take to scan a glass slide? 
A: Scan time is calculated by the time it takes to acquire the high resolution whole slide image of the tissue represented on the glass slide; most manufacturers have scan times  under 3 minutes a slide.  Scan time will typically include the overview image, focus, and acquisition of the whole slide image at either 0.5 microns/pixel (effective viewing magnification: 20X) or 0.275 microns per pixel (effective viewing magnification: 40X).  Scan time does not take into account post processing time, which is the time it may take to compress the image and transfer the image to a data management solution for viewing of the whole slide image remotely.  Other variables that contribute to variation in scan time include tissue size, capture resolution, if z-plane scanning is added, brightfield versus fluorescence, and the manufacturers specification since scan time will vary from scanner to scanner.

12. Q: Can whole slide images be integrated with my Laboratory Information System (LIS) or a snapshot put into my pathology report? 
A: Yes, the current state of integration between digital pathology systems (DPS) and anatomic pathology laboratory information systems (APLIS) provide pathologists with access to images and image analysis data from within the APLIS or the DPS. This information is then available to the Patient Report. More detailed information on this topic can be found in the DPA white paper “Interoperability between Anatomic Pathology Laboratory Information Systems and Digital Pathology Systems.”

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Telemedicine bill enables VA providers to practice across state lines

Courtesy of FierceHealthIT

By Dan Bowman  Comment |  Forward | Twitter | Facebook | LinkedIn

Telemedicine services for veterans get a shot in the arm in a new bipartisan supported bill introduced in the House last week.

The bill--the Veterans E-Health & Telemedicine Support (VETS) Act of 2012 (H.R. 6107)--would remove restrictions that currently prevent providers with the Department of Veterans Affairs from practicing across state lines if they aren't licensed in the same state as the patients they are treating. According to Glenn Thompson (R-Pa.), who introduced the bill along with Charles Rangel (D-N.Y.), veterans with mental health issues will benefit greatly from such a change.

"This bill enables the VA to expand key treatment services, including behavioral health, which is critical considering the department is facing increasing care demand and mounting provider shortages," Thompson said in a statement.

According to an announcement by Rangel, 11 other representatives have joined as co-sponsors of the bill, which also was endorsed by the American Telemedicine Association, the American Foundation for Suicide Prevention and Veterans of Foreign Wars.

The bill was proposed on the heels of the VA's announcement last week that it was launching a three-year, $15 million pilot to test the potential of providing long-distance specialty training and support to rural primary care providers who treat veterans, a program dubbed Specialty Care Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO).

Last month, the VA announced that it has set a goal of providing 200,000 remote consultations in 2012 through videoconferencing. And earlier in the year, the VA announced that it no longer would charge veterans a co-payment for any telehealth services.

To learn more:
- read the proposed bill (.pdf)
- here's Thompson's announcement
- here's Rangel's announcement

Related Articles:
VA telemedicine pilot has specialists training rural primary care docs
VA to boost remote mental health services
VA set to waive co-pays on telehealth visits
Telehealth helps single VA division save $742K

Read more about: Department of Veterans Affairstelemedicine

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Going glass to digital: virtual microscopy as a simulation-based revolution in pathology and laboratory science

Recent review article on whole slide imaging/virtual microscopy for use in education.

    Abstract

    The recent technological advance of digital high resolution imaging has allowed the field of pathology and medical laboratory science to undergo a dramatic transformation with the incorporation of virtual microscopy as a simulation-based educational and diagnostic tool. This transformation has correlated with an overall increase in the use of simulation in medicine in an effort to address dwindling clinical resource availability and patient safety issues currently facing the modern healthcare system. Virtual microscopy represents one such simulation-based technology that has the potential to enhance student learning and readiness to practice while revolutionising the ability to clinically diagnose pathology collaboratively across the world. While understanding that a substantial amount of literature already exists on virtual microscopy, much more research is still required to elucidate the full capabilities of this technology. This review explores the use of virtual microscopy in medical education and disease diagnosis with a unique focus on key requirements needed to take this technology to the next level in its use in medical education and clinical practice.

    J Clin Pathol doi:10.1136/jclinpath-2012-200665
    1. Danielle Nelson1
    2. Amitai Ziv2,3
    3. Karim S Bandali1

    1. 1The Michener Institute for Applied Health Sciences, Toronto, Ontario, Canada

    2. 2The Israel Center for Medical Simulation, Sheba Medical Center, Tel-Hashomer, Israel

    3. 3Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    1. Correspondence to: Dr Karim S Bandali, The Michener Institute for Applied Health Sciences, 222 St Patrick Street, Toronto, Ontario M5T 1V4, Canada; kbandali@michener.ca
    • Accepted 24 April 2012
    • Published Online First 12 July 2012

     

    Source:
    http://feeds.feedburner.com/DigitalPathologyBlog

    Seldom wrong, never in doubt

    MclogoThe need, impact, importance and disagreement rate for second opinion pathology referrals has been a constant topic of discussion for many years.  These second opinions generally come in two flavors.  The first is a consultation of a particularly challenging case by a pathologist or clinician.  Patients can also initiate these consults if they are uncomfortable with a diagnosis.  The second flavor is the review of pathology diagnoses of patients now seeking treatment at a new institution who were originally diagnosed by an outside pathologist from the referring institution.  The popular press contains many stories about misdiagnoses in patients and mismanagement until second opinion/expert review identified a problem with the original pathology review.  The pathology literature contains dozens of studies and meta-analyses looking at disagreement rates from referral centers looking at "us versus them", working off the notion that the second opinion/referral/expert diagnosis is "the right one", "the gold standard" or represents "the absolute truth" for treatment, management, outcomes measurements and classification for subsequent tissue/molecular studies.  In a similar, but distinctly different scenario, pathologists, clinicians and patients can each seek a "second opinion" or consultation on challenging cases or diagnoses they are uncomfortable with.

    Here is the typical scenario and how this works:

    SecondOpinion2"Most people never consider the possibility of getting a second opinion on the pathology report from which the diagnosis was made, but the entire plan of treatment depends on what kind of cancer you have and how far it has spread, both of which usually depend in part or whole on the pathologists interpretation of the biopsy or surgical specimen. Changes in the interpretation of the pathology can dramatically change both the treatment and the prognosis.

    At the same time, most patients probably do not need a second pathology opinion. There are some common sense cues that can let you know if it might make sense. I think that if you have a really rare cancer, it is always advisable to get a second pathology opinion.

    If your pathology report doesn't give a definite diagnosis, a second opinion is probably in order.

    Your hospital/group name here Pathology Department has the expertise to diagnose and classify all types of cancer, which helps oncologists choose the most effective treatment method for their patients. We provide second opinion evaluation of tissue samples submitted by physicians and pathologists for patients outside Your health care system name here.

    We have experts in a wide range of cancer subspecialties, including:

    • Breast
    • Dermatopathology
    • Gastrointestinal
    • Genitourinary
    • Gynecological
    • Head and neck
    • Neuropathology
    • Bone and soft tissue
    • Thoracic

    SecondopinionFees must be paid at time of the review. Many insurance carriers will reimburse the costs of second opinion consultations. If payment is a problem, we can work with you. Follow-up reviews are payable separately. Please remember that our service is for pathology second opinions only. We cannot discuss or recommend treatment options."

    Consultations in pathology are an integral and routine part of daily practice.  Except for the pathologist or the group that claims "I/we don't send anything out".  That person/group may not but informed patients/clinicians will.  As a resident I was warned if you don't show cases to others or get consults from external sources you are doing your patients and yourself a disservice.  

    Institutions/individuals who provide second opinion reads as part of or exclusively as their practice of pathology have from time to time, in many subspecialties made claims about disagreement rates that justify the practice for risk management and appropriate patient management with published disagreement rates from 2-5%, depending on the specimen tissue source or part type.  There is also the issue of defining what constitutes a "disagreement", although most studies cite a difference that would alter prognosis or treatment.

    Teleconsultations using whole slide imaging, as frequent readers know, I think are one of the many use cases/applications for digital pathology.  Mitigating slide handling issues, improving turn around time, retaining original glass slides onsite, reviewing cases with your consultant in real-time and education/training from external review at another site.

    A recent paper shows that, in general, there is a very high level of agreement among pathologists for secondary review of pathology for referral patients, in this study, a rate of 99.4% agreeement.  While small (0.6%), the diagnostic differences may be highly clinically significant, arguing that secondary review of pathology materials should be standard of care.  This high agreement rate should allay concerns of patients and clinicians (and perhaps some pathologists) alike regarding the value and consistency of diagnoses rendered by the pathology community at large.

    With such high agreement, why not digital pathology for second opinions/specimen review for patient referrals/slide review prior to additional surgery/treatment?

    And in some cases, with follow up case sharing, even outsmart the consultant?

    Ryan Swapp, M.D., Marie Christine Aubry, M.D., Diva Salomao, M.D., and John Cheville, M.D., all of Mayo Clinic’s Division of Anatomic Pathology, recently released a study, “Outside Case Review of Surgical Pathology for Referred Patients: The Impact on Patient Care,” that can now be found as an early online release in CAP Archives of Pathology & Laboratory Medicine.

    ChickenThe Division of Anatomic Pathology reviewed the pathology of nearly all patients that were referredto Mayo Clinic for treatment from 2005-2010. The objective was to identify the rate of major disagreements with diagnoses from external institutions and to characterize the nature and impact of discordant diagnoses on patient care.

    Interestingly, they also concede that that their review diagnosis was not always the correct one.

    Summary:  Major disagreements occurred only 0.6% of the time (457 of 71,811 cases) from 2005-2010.  The most frequent areas of disagreement were gastrointestinal (80 cases; 17.5%), lymph node (73;16.0%), bone/soft tissue (47; 10.3%), and genitourinary(43; 9.4%).  The disagreeing diagnosis was not always the correct one.  In a subset of these cases for which additional tissue was taken (n=86 disagreements from July 2009 – Dec 2010), this subsequent tissue showed that the original diagnosis was correct 15.1% of the time (13 of 86 cases).

    View Full Study

     

    Source:
    http://feeds.feedburner.com/DigitalPathologyBlog

    Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach

    Automated image analysis of cells and tissues has been an active research field in medical informatics for decades but has recently attracted increased attention due to developments in computer and microscopy hardware and the awareness that scientific and diagnostic pathology require novel approaches to perform objective quantitative analyses of cellular and tissue specimens. Model-based approaches use a priori information on cell shape features to obtain the segmentation, which may introduce a bias favouring the detection of cell nuclei only with certain properties. In this study we present a novel contour-based “minimum-model” cell detection and segmentation approach that uses minimal a priori information and detects contours independent of their shape. This approach avoids a segmentation bias with respect to shape features and allows for an accurate segmentation (precision = 0.908; recall = 0.859; validation based on ?8000 manually-labeled cells) of a broad spectrum of normal and disease-related morphological features without the requirement of prior training.

    Full article


     

    Source:
    http://feeds.feedburner.com/DigitalPathologyBlog

    Digital Pathology Association Regulatory Committee Offerings

    The Digital Pathology Association has established a regulatory committee; the committee goal is to create a sense of urgency within regulatory agencies and to bring clarity to the digital pathology clearance and approval process. 

    At Pathology Visions 2011 a Regulatory Panel of experts convened with representatives from the U.S. Food and Drug Administration (FDA), the Centers for Medicaid and Medicare Services (CMS), and the College of American Pathologists (CAP).  The DPA regulatory committee presented a series of questions for the panel to address.  DPA members can view the panel experts presentations and the panel recording “Navigating Digital Pathology’s Path to Patients” within the Member Community.

    Choose one of categories below:

    FDA

    CMS/CLIA

    CAP

    FDA

    In the United States, technology manufactured for digital pathology (i.e. scanners, software) are considered medical devices and are regulated by the U.S. Food and Drug Administration (FDA). Manufacturers may market their digital pathology technology for Research Use Only (RUO) unless the FDA has issued a clearance or approval to a specific manufacturer and for an intended use of the digital pathology hardware and software.  Several manufacturers have received one or more FDA 510(k) clearances, however no manufacturer has yet received an FDA approval of their technology for primary diagnosis.
     
    The FDA remains focused on the safety and the effectiveness of digital pathology.  Safety is defined in 21 CFR 860.7(d)(1) as the “Reasonable assurance, based on valid scientific evidence, that the probable benefits to health from use of the device for its intended uses and conditions of use, when accompanied by adequate directions and warnings against unsafe use, outweigh any probable risks.”   Effectiveness is defined in 21 CFR 860.7(e)(1) as “Reasonable assurance, based on valid scientific evidence, that in a significant portion of the target population, the use of the device for its intended use and conditions of use, when accompanied by adequate directions for use and warning against unsafe use, will provide clinically significant results.”

    In October 2009 the FDA Hematology and Pathology Devices Panel held a meeting to gain expert opinion and industry feedback on the replacement of H&E glass slides and conventional microscopy by whole slide images (WSI), specifically for rendering a routine surgical pathology diagnosis of a disease or condition.  No formal guidance document has been issued by the FDA for digital pathology, however one is expected soon.  In the meantime the FDA has provided two guidance documents, IVD 
    Diagnostic products Labeled for Research Use Only and Mobile Medical Applications, that are relevant to digital pathology. 

    Pathology Visions 2011 Presentations (Members Only)
    - Regulatory Panel | Navigating Digital Pathology’s Path to Patients (Members Only)
    Digital Pathology 510(k) Clearances
    FDA October 2009 meeting materials and transcriptions
    - FDA issued guidance documents relevant to digital pathology
        1. IVD Diagnostic Products Labeled for RUO/IUO
        2. Mobile Medical Applications

    CMS/CLIA

    Centers for Medicare and Medicaid Services (CMS) oversees the Clinical Laboratory Improvement Amendments (CLIA) which regulate all non research, laboratory tests preformed on humans in the U.S. The goal of CLIA is to insure quality laboratory testing, and therefore quality control (QC) portions of CLIA will apply to digital pathology;  including the analytic phase of testing which requires monitoring the testing personnel, the test system, and the laboratory environment. Other requirements that apply to all testing include calibrations, establishing or verifying performance specifications, test system or equipment maintenance, test results comparisons, corrective actions, having a back-up plan for instrument failure, and a procedure manual.  Validation of a digital pathology system is also necessary, and labs should follow CLIA requirements for test reports. 

    In February 2012 Clinical Laboratory Improvement Advisory Committee (CLIAC) held a meeting which discussed emerging issues in digital pathology. CLIAC provides scientific and technical advice and guidance to the Secretary of Department of Health and Human Services (HHS); the Assistant Secretary for Health; the Director of Centers for Disease Control and Prevention (CDC); the Commissioner of the Food and Drug Administration (FDA); and the Administrator of the Centers for Medicare and Medicaid Services (CMS). The advice and guidance pertain to general issues related to improvement in clinical laboratory quality and laboratory medicine.  CLIAC may also provide advice and guidance on specific questions related to a possible revision of CLIA standards. 

    Validation of Digital Pathology in a Healthcare Environment
    Pathology Visions 2011 Presentations (Members Only)
    - Regulatory Panel | Navigating Digital Pathology’s Path to Patients (Members Only)
    Current CLIA Regulations
    Summary of CLIAC February 2012 Meeting

    CAP

    The College of American Pathologists (CAP) is a CLIA accredited organization composed of board-certified pathologists with a mission to serve patients, pathologists, and the public through the advocation of excellence in pathology and laboratory medicine worldwide. 

    CAP issues laboratory accreditation checklists which support the accreditation process.  The checklists align with the CLIA mandate of high quality laboratory testing by providing a solid foundation for excellence in patient safety, and compliance with policies, procedures, and laboratory processes.  The Anatomic Pathology, Laboratory General, and Cytopathology checklists have items that can apply to digital pathology systems.  

    In 2011 a CAP Center working group was formed to create guidelines for digital pathology.  Thirteen guidelines were developed to assist the pathology community with validating WSI for clinical diagnostic use.  The thirteen guidelines, which are still under development, were presented at Pathology Visions 2011.  The final version of the guidelines has not been issued but is expected soon.  

    Download the DPA white paper, Validation of Digital Pathology in a Healthcare Environment, for more specific information about the CAP checklist items and the draft guidelines. 

    Validation of Digital Pathology in a Healthcare Environment
    Pathology Visions 2011 Presentations (Members Only)
    - Regulatory Panel | Navigating Digital Pathology’s Path to Patients (Members Only)
    The College of American Pathologists' Laboratory Accreditation Program (CAP-LAP) Practical World View on Digital Pathology from a CLIA Accreditation Provider (Members Only)
    - Recommendations for Validating Whole Slide Imaging in Pathology: College of American Pathologists (CAP) Pathology and Laboratory Quality Center (Members Only)
    CAP Checklists

     

    Source:
    http://feeds.feedburner.com/DigitalPathologyBlog

    "Dissection as Studio Practice with Real Anatomical Specimens," Class with Laura Splan, Observatory, Next Monday, July 23

    I am very excited about "Dissection as Studio Practice," a class taking place next Monday, July 23, at Observatory. Taught by artist Laura Splan, the class will begin with an illustrated survey of the use of notions of "dissection" in contemporary art practice; these principles will then be applied to in-class projects which include the dissection of your very own anatomical specimens (i.e. frog, sheep brain, cow eye). This class is open to all expernience levels, and participants are invited to bring additional materials, objects and artifacts that will inspire their “dissective” inclinations.

    We had a wonderful time in the last iteration of this class, as you can see from the photos above. Full description of the class follows. Class size is limited; if interested, be sure to RSVP via email to morbidanatomy[at]gmail.com. You can see more of Laura Splan's work by clicking here. Hope very much to see you there!

    Lecture and Studio Art and Dissection Class with artist Laura Splan
    Date: Monday, July 23
    Time: 7-10 PM
    Fee: $75
    *** Class size is limited to 16; please RSVP to morbidanatomy[at]gmail.com

    This class is part of the
    Morbid Anatomy Art Academy

    This class will survey the use of dissection in contemporary art practice through an illustrated lecture, specimen dissections, and studio time for individual and collaborative projects. We will examine the conceptual and cultural significance of cutting, excavating, disassembling, labeling, observing and displaying “bodies.” The lecture will present a brief history of dissection as well as work by contemporary artists exploring imagery, tropes and methods of dissection. The collaborative and individual art projects will be fun and lively hands on explorations of the meaning of dissection in a work of art. Each student will receive a complete specimen dissection kit (i.e. frog, sheep brain, cow eye) to create a self-directed dissection project with. Participants should bring additional materials, objects and artifacts that will inspire their “dissective” inclinations. Additional supplies will be provided by the instructor to stimulate your creativity. No prior art training is required. Everyone is welcome.

    Laura Splanis a Brooklyn based visual artist. Her mixed media work explores historical and cultural ambivalence towards the human body. She was a Visiting Lecturer at Stanford University where she taught “Art and Biology”. She has been a Visiting Artist at the New York Academy of Sciences, California College of Art, San Francisco Art Institute, Maryland Institute College of Art, and Cal Arts. Her artwork was recently commissioned by the CDC Foundation. She curates the visual portal DomesticatedViscera.com. Images of her artwork can be found on her website: LauraSplan.com. You can find out more here. Feel free to contact Laura through her website with any questions about the class by clicking here. You can see photos from the last class by clicking here.

    You can find out more here, and RSVP with an email to morbidanatomy[at]gmail.com.

    Source:
    http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss

    "Dissection on Display: Cadavers, Anatomists and Public Spectacle" by Christine Quigley, Book Review by Bess Lovejoy

    I am very excited to read the new and wonderful looking book Dissection on Display: Cadavers, Anatomists and Public Spectacle by Christine Quigley, who many of you might best know as editor of the wide-ranging blog Quigley's Cabinet. I have not yet had a chance to read the book, but we are all in luck, as friend of Morbid Anatomy Bess Lovejoy--author of the forthcoming Rest in Pieces: The Curious Fates of Famous Corpses--has kindly offered up a very detailed and thoughful review of the book special for the Morbid Anatomy blog.

    Lovejoy's review follows; you can also find out more about the book--or purchase a copy of your very own--by clicking here.

    Dissection on Display: Cadavers, Anatomists and Public Spectacle
    By Christine Quigley
    Mcfarland, February 24, 2012

    Most of us have never seen a dead body, let alone witnessed the dissection of a cadaver. But for centuries in Europe, Britain, and America, public dissections were highly social occasions. In the candlelit, damask-draped anatomy theatre of 18th century Bologna, townspeople jostled medical students and high-ranking officials during a two-week-long dissection that took place as part of the annual carnival. In 16th century Britain, hundreds crowded around to watch the dissections of executed criminals. And in early 19th century America, the most fashionable strata of society (men and women alike) attended public dissections for a chance to “see and be seen.”

    In her new book, Dissection on Display: Cadavers, Anatomists and Public Spectacle, scholar, author, and blogger Christine Quigley traces the hidden history of anatomists who perform for the public. Not all of the men she profiles are known just for their dissections: some, like 17th and 18th century Europeans Frederik Ruysch and Honoré Fragonard, did the dirty work in private, then displayed the exquisitely-crafted results to the public in the form of art and illustration. Many of the names Quigley profiles will be familiar to Morbid Anatomy readers, though others -- like Thomas “Mummy” Pettigrew, the 19th century London antiquarian who unrolled mummies to entertain his guests – may be fresh discoveries.

    Using a series of thematically-grouped vignettes, Quigley explores anatomists as demonstrators, educators, collectors, showmen, and more. Some of the book’s most intriguing passages deal with the lessons that public dissections were supposed to impart: not just about the workings of the body, but the workings of God, and of justice. Even more than a chance to gain medical wisdom, public dissections were often promoted as an opportunity to witness the glory of God in the functioning of a corpse’s entrails. Sometimes they were also seen as a chance to exult in the final stage of  punishment meted out to a criminal. The mutilation of the corpse was thought to deny the deceased a chance at Resurrection -- thus condemning him or her both in life and afterlife.

    Quigley also touches on the racial and sexual undertones that have long troubled the study of anatomy. One of the book’s most disturbing sections profiles French naturalist and zoologist Georges Cuvier and his quest to uncover (literally) the mysteries that lay between the legs of Saartjie Bjartmaan, also known as the “Hottentot Venus.” Bjartmaan – a young Khoisan woman from South Africa -- entertained audiences in early 19th century London and Paris with the enormous size of her buttocks. Some whispered that Bjartmaan was also blessed with a similarly enormous labia minora, and like other scientists of the time, Cuvier was fascinated by such rumors. After Bjartmaan’s death, he detailed her dissection in a medical journal and preserved both her brain and genitals in greenish glass bottles outside his office. Thus the last shred of modesty that Bjartmaan had protected in life was unceremoniously stripped from her in death, in a way that calls to mind the brutally frank autopsy reports of modern dead celebrities.

    Today, human dissection is usually hidden from the public. This cloaking began in the 19th century, when, as Quigley writes, “The anatomists withdrew behind the doors of educational institutions, and the townspeople were not invited to join them.” These days dissections occur exclusively in a medical or forensic context, and the only corpses we see are on television. No longer is the public treated to theatrical displays of their own inner-workings, as they were in the days when Andreas Vesalius kept Renaissance audiences glued to their seats.

    But there have been exceptions. In 2002, the controversial Gunter von Hagens – he of the plastinated corpses and Body Worlds exhibits – staged a ticketed dissection of the body of a 72-year-old man in London. The event drew considerable attention, and Hagens faced the threat of arrest even while wielding the scalpel. Yet the room was packed, proving that our appetites for dissection haven’t waned. Quigley includes an excellent photograph of the event, notable not for the pale cadaver about to be sliced apart, but for the front row of the audience, their faces horrified, bemused, and fascinated in turn. One woman crosses her hands over her chest in protection, clutching her check and beginning to grimace. Next to her, an older gentleman folds his wrists behind his elbows and leans back as if to say “show me what you got.” Von Hagens himself is at the forefront of the image, clad in a black fedora -- his nod to Rembrandt’s “The Anatomy Lesson of Dr. Nicolaes Tulp,” which hangs on the wall above him.

    In fact, Quigley takes pains to show us how conscious Von Hagens – the most famous modern anatomist -- is of his historical lineage. (Many of his most famous pieces, such as his flayed horse and rider, quote directly from the work of earlier anatomists such as Fragonard.) This is where the book shines: Quigley has stitched together a family tree of public anatomists who contributed to our understanding of the body, but whose work often remains hidden like the organs beneath our skin. Dissection on Display is recommended reading for anyone with a healthy sense of curiosity, morbid or otherwise, about what used to happen when we were allowed to watch.

    The writer of this post, Bess Lovejoy, is a writer, editor, and researcher based in Seattle. Her book Rest in Pieces: The Curious Fates of Famous Corpsesis coming out March 2013. You can find out more about her at her website besslovejoy.com." To find out more--or to purchase a copy of this book--click here.

    Image: The Anatomy lesson of Dr Nicolaes Tulp, Remrandt van Rijn, 1632; found on Wikipedia. According to Quigley, the dissection was performed in Leiden’s anatomical theatre, and included an audience of townspeople that were left out of the painting. Instead, Rembrandt was paid to include surgeons who may or may not have actually been there.

    Source:
    http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss

    Living Faith

    Arturo Francisco Olivas paints traditional retablos for Spanish Market in his Albuquerque studio. Photo Credit Jim Thompson/Journal

    Arturo Francisco Olivas will be selling about 40 of his retablos at Traditional Spanish Market in Santa Fe next weekend. But there is a one retablo Olivas has made that will be staying home. Its San Peregrin, the patron saint of cancer victims.

    Olivas, an Albuquerque resident, is living with cancer.

    He is one of more than 350 Hispanic artists showing such traditional artwork as retablos, bultos, straw appliqu and tinwork at the juried market.

    Last July I painted the retablo before I knew I had cancer, the 53-year-old Olivas said.

    Three months later, he was diagnosed with advanced lung cancer and hospitalized. He took medical leave from his bilingual teaching position with the Rio Rancho public schools. Then last December he decided, based on his doctors advice, to retire.

    The doctor had given me eight to 12 months to live. His advice is Do whatever it is you need to do. I decided I couldnt continue teaching because I needed to use my energy to get well, Olivas said.

    The cancerous tumors, he said, had spread to his brain, ribs and spine. Initially, he was given steroid therapy, then radiation treatment. On the advice of an oncologist, Olivas began long-term chemotheraphy treatment via a daily pill.

    The chemo has shrunk the tumors and they have not spread to any other part of my body, he said.

    Though the treatment leaves him debilitated, his days in retirement allow him more time for his art. He cuts and shapes the wood for the retablos in his backyard patio-workshop and paints them in the santos room inside his welcoming walled home.

    Read this article:

    Living Faith

    NASA Hypersonic Inflatable Tech Test Set

    NASA Space Technology Program researchers plans to launch and deploy a large inflatable heat shield aboard a rocket traveling at hypersonic speeds this weekend during a technology demonstration test from the agency's Wallops Flight Facility on Wallops Island, VA. NASA has four consecutive days of launch opportunities for the agency's Inflatable Re-entry Vehicle Experiment (IRVE-3), starting July 22, with the liftoff window from 0600-0800 EDT each day.

    The test is designed to demonstrate lightweight, yet strong, inflatable structures that could become practical tools for exploration of other worlds or as a way to return items safely to Earth from the International Space Station. During this technology demonstration test flight, NASA's IRVE-3 payload will try to re-enter Earth's atmosphere at hypersonic speeds -- Mach 5, or 3,800 mph to 7,600 mph.

    "As we investigate new ways to bring cargo back to Earth from the International Space Station and innovative ways to land larger payloads safely on Mars, it's clear we need to invest in new technologies that will enable these goals," said Michael Gazarik, director of NASA's Space Technology Program. "IRVE-3 is precisely the sort of cross-cutting technology NASA's Space Technology Program should mature to make these future NASA and commercial space endeavors possible."

    The IRVE-3 experiment will fly aboard a three-stage Black Brant XI launch vehicle for its suborbital flight. The payload and the heat shield, which looks like a large, uninflated cone of inner tubes, will be packed inside the rocket's 22-inch-diameter nose cone. About six minutes after launch, the rocket will climb to an altitude of about 280 miles over the Atlantic Ocean. At that point, the 680-pound IRVE-3 will separate from the rocket. An inflation system similar to air tanks used by scuba divers will pump nitrogen gas into the IRVE-3 aeroshell until it becomes almost 10 feet in diameter. Instruments on board, including pressure sensors and heat flux gauges, as well as cameras, will provide data to engineers on the ground of how well the inflated heat shield performs during the force and heat of entry into Earth's atmosphere.

    After its flight, IRVE-3 will fall into the Atlantic Ocean about 350 miles down range from Wallops. From launch to splash down, the flight is expected to take approximately 20 minutes. "We originally came up with this concept because we'd like to be able to land more mass and access higher altitudes on Mars," said Neil Cheatwood, IRVE-3 principal investigator at NASA's Langley Research Center in Hampton, Va. "To do so you need more drag. We're seeking to maximize the drag area of the entry system. We want to make it as big as we can. The limitation with current technology has been the launch vehicle diameter."

    Cheatwood and a team of NASA engineers and technicians have spent the last three years addressing the technical challenges of materials withstanding the heat created by atmospheric entry and preparing for the IRVE-3 flight. The team has studied designs, assessed materials in laboratories and wind tunnels, and subjected hardware to thermal and pressure loads beyond what the inflatable spacecraft technology should face during flight.

    This test is a follow on to the successful IRVE-2, which showed an inflatable heat shield could survive intact after coming through Earth's atmosphere. IRVE-3 is the same size as IRVE-2, but has a heavier payload and will be subjected to a much higher reentry heat.

    IRVE-3 is part of the Hypersonic Inflatable Aerodynamic Decelerator (HIAD) Project within the Game Changing Development Program, part of NASA's Space Technology Program. Langley developed and manages the IRVE-3 and HIAD projects.

    (NASA Image IRVE-3 inflation system)

    Read the original post:

    NASA Hypersonic Inflatable Tech Test Set

    NASA Scopes Out Another Exoplanet That's Two-Thirds the Size of Earth

    [Credit: NASA/JPL-Caltech]NASA's range of telescopes continually manage to surprise and delight with their frequent discoveries of planets far, far away--some of which are particularly quirky. While Kepler may be the best known of these telescopes, this time the Spitzer Space Telescope made a pretty interesting discovery this week: an exoplanet two-thirds the size of Earth.

    This may not seem like such a big deal, but it's not very common for us to find exoplanets (planets outside of our own solar system) to be smaller than Earth in size, or us to fine one so relatively close. The planet, named UCF-1.01, is "just" 33 light years away. Additionally, Spitzer is normally used to study exoplanets already discovered and not to discover new exoplanets, so this is not only a first for the telescope, but a potential new role in for it.

    Size-wise, UCF-1.01 is around 5,200 miles in diameter, and was discovered when scientists were using Spitzer to study Neptune-sized exoplanet GJ 436b, which orbits the red-dwarf star GJ 436. Scientists noticed "dips" in the infrared coming from the star that were not caused from GJ 436b passing by it. This in turn led to the discovery of UCT-1.01. Its year lasts only about 1.4 Earth days due to how close the planet orbits its star.

    The planet's temperatures are around 1,000 degrees Fahrenheit, meaning there's very little in terms of atmosphere. This isn't surprising, considering how closely it orbits its sun. Scientists believe the planet itself has melted slightly, causing a molten surface.

    It's a precious discovery, considering that of the 1,800 planetary candidates discovered by NASA, only three were smaller than Earth. Three. You can find out more about the Spitzer Space Telescope and its missions on NASA's website.

    [NASA]

    Get more GeekTech: Twitter - Facebook - RSS | Tip us off | Follow Elizabeth Fish

    Read more here:

    NASA Scopes Out Another Exoplanet That's Two-Thirds the Size of Earth

    Tiny particles: Big potential or big threat?

    Kristin Conn puts non-nano sunscreen on her son, Merrick, at Lee Street Beach in Evanston, Illinois. While nano materials offer benefits, such as clear sunscreens, some people worry about the effects they can have if absorbed into the body. (Chicago Tribune/MCT: Chris Sweda)

    CHICAGO -- Zinc oxide would be the perfect sunscreen ingredient if the resulting product didn't look quite so silly. Thick, white and pasty, it was once seen mostly on lifeguards, surfers and others who needed serious sun protection.

    But when the sunscreens are made with nanoparticles, the tiniest substances that humans can engineer, they turn clear -- which makes them more user-friendly.

    Improved sunscreens are just one of the many innovative uses of nanotechnology, which involves drastically shrinking and fundamentally changing the structure of chemical compounds. But products made with nanomaterials also raise largely unanswered safety questions -- such as whether the particles that make them effective can be absorbed into the bloodstream and are toxic to living cells.

    Less than two decades old, the nanotech industry is booming. Nanoparticles -- measured in billionths of a meter -- are already found in thousands of consumer products, including cosmetics, pharmaceuticals, antimicrobial infant toys, sports equipment, food packaging and electronics. In addition to producing transparent sunscreens, nanomaterials help make light and sturdy tennis rackets, clothes that don't stain and stink-free socks.

    The particles can alter how products look or function because matter behaves differently at the nanoscale, taking on unique and mysterious chemical and physical properties. Materials made of nanoparticles may be more conductive, stronger or more chemically

    "Everything old becomes new when miniaturized," said Chad Mirkin, director of the International Institute for Nanotechnology at Northwestern University. "This gives scientists a new playground, one focused on determining what those differences are and how they could be used to make things better."

    But the development of applications for nanotechnology is rapidly outpacing what scientists know about safe use. The same unusual properties that make nanoscale materials attractive may also pose unexpected risks to human health and the environment, according to the scientific literature.

    "We haven't characterized these materials very well yet in terms of what the potential impacts on living organisms could be," said Kathleen Eggleson, a research scientist in the Center for Nanoscience and Technology at the University of Notre Dame.

    Scientists don't yet know how long nanoparticles remain in the human body or what they might do there. But research on animals has found that inhaled nanoparticles can reach all areas of the respiratory tract; because of their small size and shape, they can migrate quickly into cells and organs. The smaller particles may also pose risks to the heart and blood vessels, the central nervous system and the immune system, according to the Food and Drug Administration.

    See the rest here:

    Tiny particles: Big potential or big threat?

    Nightcore Party Covers Mix #3 – Video

    21-07-2012 16:36 I originally had in mind uploading this on the 20th July, which is my birthday, but some issues unfortunately showed up, so I had to remake it and rerender it, but anyway, here it is, and that is what matters. Hope you all enjoy! Facebook: (A like is always appreciated) Website: Please leave a like and a comment 🙂 Share to let your friends know! PLEASE READ: I do not own anything in? this video, including the audio and picture. The credits go to their respective owners. This video is purely fan-made, and will not be used for profit or illegal sharing. Fair Use: "Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use." You'll find the pictures on the Facebook fan page 🙂 ?SUBSCRIBE?

    See the article here:

    Nightcore Party Covers Mix #3 - Video

    Knee Pain is Now Being Treated with Regenerative Medicine at The Center for Regenerative Medicine

    "Knee pain is now being treated with regenerative medicine at The Center for Regenerative Medicine," according to Doctor Farshchian an orthopedic regenerative practitioner at the center for regenerative medicine.(PRWEB) July 22, 2012 "Knee pain is now being treated with regenerative medicine at The Center for Regenerative Medicine," according to A.J. Farshchian MD an orthopedic regenerative ...

    Read the original post:

    Knee Pain is Now Being Treated with Regenerative Medicine at The Center for Regenerative Medicine

    Cooper Medical School of Rowan University to host grand opening celebration

    CAMDEN Cooper Medical School of Rowan University is hosting its long-awaited grand opening Tuesday, marking a monumental milestone for both the university and the hospital.

    In June 2009, Rowan University and the Cooper Health System decided together to address the physician shortage locally and nationally, as well as to improve health care throughout the region.

    They approached us and we said, Yeah, were in. Lets do it, Rowan University spokesman Joe Cardona said. We were ready and willing while other folks werent.

    According to Cardona, Cooper had long been on the quest for its own four-year medical school for decades and turned to Rowan University when other entities didnt have the wherewithal to partner.

    That same year, then-state Gov. Jon Corzine signed an executive reorganization order that would create a new allopathic medical school in Camden.

    Three years later, the new six-story educational building will be the 135th medical school in the ground and the first new medical school in the state in more than 35 years.

    With only a few finishing touches remaining before the opening this week, Dr. Paul Katz, founding dean of CMSRU, gave South Jersey Sunday a sneak-peak of the 200,000-square-foot, $139 million facility.

    The 25 active learning rooms, a learning commons room and satellite medical library, the Clinical Simulation Center and laboratory and research space are all designed to breed hands-on healers of the future.

    Our theme is hi-tech, hi-touch, Katz said, overlooking the 250-seat auditorium, which, like many of the learning spaces in the building, is fitted for audio and visual recording for future reference and review for students and alumni.

    We wanted this to be an experience thats not sterile, Katz said.

    Read more here:

    Cooper Medical School of Rowan University to host grand opening celebration